MHRAsafety guidance83% confidence
Opportunities for patients and the public to be involved in the work of the MHRA
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (cardiology) as Anthos Therapeutics.
Regulatory Analysis
How we engage and involve patients and the public in our regulatory decision-making.
Supporting Context
- Therapeutic area
- Cardiology · Atrial Fibrillation
- Sub-indication
- Hypertension
Related signal: Anthos and Novartis initiate LILAC-TIMI 76 trial for abelacimab in high-risk AF patients